Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| CALGB-40503 | CALGB | Endocrine Therapy with or without ANTI-VEGF Therapy: A Randomized; Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| CALGB-40601 | CALGB | Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| CALGB-49808 | CALGB | A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA; IIIB or Regional Stage IV Breast Cancer **ADMINISTRATIVELY COMPLETED as of December 15; 2002** | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-49907 | CALGB | A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens; Cyclophosphamide; Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC); Versus Capecitabine in Women 65 Years and Older with Node Positive or Node Negative Breast Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-50303 | CALGB | Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-70301 | CALGB | Quality of Life; Employment; and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes: Companion to CALGB 40101 | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-80101 | CALGB | Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-80203 | CALGB | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with and without Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-80303 | CALGB | A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC #704865 IND# 7921) Versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| CALGB-80702 | CALGB | A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |